Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury
NCT ID: NCT07197957
Last Updated: 2025-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2025-03-11
2027-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cystatin c: a Biomarker of AKI in Aneurysmal Subarachnoid Haemorrhage Patients
NCT06635408
Plasma Cystatin C and Acute Kidney Injury
NCT01652755
Serum Cysteine Rich Protein 61 and Cystatin C for Early Detection of Acute Kidney Injury in Patients With Heart Diseases
NCT05242705
Acute Kidney Injury in Newborns With Perinatal Asphyxia
NCT03617055
Evaluating Novel Biomarkers in Acute Kidney Injury
NCT01573104
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To evaluate the effect of patient characteristics in the Cystatin C based GFR estimation in comparison to Cr based estimation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Inpatients with CKD (Figure 1)
* Order for CT imaging study or coronary angiography with isohexol Omnipaque) contrast media.
* Pre and post contrast available
* All races and ethnicity of patients are eligible. We expect to analyze approximately equal number of men and women in this study.
Exclusion Criteria
* Patients under the age of 18 years
* Pregnancy
* Incarcerated individuals
* Patients with impaired cognition and unable to follow consent procedures
* Recent exposure to CM (within 2 days before/after procedure)
* Cardiac shock
* Medications that affect biomarkers, including corticosteroids, lfamethoxazoletrimethoprim
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BayCare Health System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Morton Plant Hospital
Clearwater, Florida, United States
Morton Plant North Bay Hospital
New Port Richey, Florida, United States
Mease Countryside Hospital
Safety Harbor, Florida, United States
St. Anthony's Hospital
St. Petersburg, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cystatin & Early AKI Detection
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.